Strumento inattivo

Altre lingue InMed Pharmaceuticals Inc. Toronto S.E.

Azioni

IN

CA4576376012

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board	18/04
InMed Pharmaceuticals Inc. Appoints David G. Morgan to its Scientific Advisory Board	18/04
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration	16/04
InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease	04/04
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies	04/04
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance	20/03
InMed Pharmaceuticals Inc. Provides Update on Pharmaceutical Development Programs	13/02
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update	13/02
InMed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13/02
InMed Pharmaceuticals Inc. Announces Chief Financial Officer Changes, Effective February 20, 2024	09/02
InMed Pharmaceuticals Inc. Announces Executive Changes, Effective February 20, 2024	09/02
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer	09/02
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET	18/01
InMed Pharmaceuticals Provides Business Update and Milestones for 2024	16/01
InMed Announces Results of 2023 Annual General Meeting	20/12
Inmed Pharmaceuticals Inc. Announces the Launch of Inm-089	29/11
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration	29/11
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update	14/11
InMed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14/11
InMed Pharmaceuticals Inc. Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch 2023	02/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue InMed Pharmaceuticals Inc. Toronto S.E.

Azioni

IN

CA4576376012

Altre lingue

Filtri